Brian Lian
CIK 1614578 · President & CEO · last filed 2026-07-29
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$86.36M
Companies
3
Total Filings
60
Lifetime Open-Market Net
-$74.66M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VKTX | President & CEO | 2,720,958 | $31.74 | $86.36M | -$74.66M | 27 | 2026-07-29 |
| SEELOS THERAPEUTICS, INC. (SEEL) Delisted | Director | — | $0.39 | — | $0 | 6 | 2024-01-08 |
| Viking Therapeutics, Inc. (VKTXW) Delisted | President & CEO | 1,894,181 | $4.60 | $8.71M | $0 | 10 | 2021-01-19 |
Recent Filings · Page 5 of 6
60 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-01-04 | VKTX | Mixed | +225,336 | -$1.44M | EDGAR |
| 2022-01-06 | SEELOS THERAPEUTICS, INC. (SEEL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-01-05 | VKTX | Mixed | +110,582 | -$299.4K | EDGAR |
| 2021-09-30 | VKTX | Mixed | +27,750 | -$180.4K | EDGAR |
| 2021-01-19 | Viking Therapeutics, Inc. (VKTXW) Delisted | Tax (F) | −5,611 | -$37.5K | EDGAR |
| 2021-01-08 | SEELOS THERAPEUTICS, INC. (SEEL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-01-06 | Viking Therapeutics, Inc. (VKTXW) Delisted | Mixed | +155,815 | -$276.0K | EDGAR |
| 2020-09-16 | Viking Therapeutics, Inc. (VKTXW) Delisted | Mixed | +36,308 | -$120.0K | EDGAR |
| 2020-01-21 | Viking Therapeutics, Inc. (VKTXW) Delisted | Tax (F) | −3,195 | -$22.9K | EDGAR |
| 2020-01-07 | SEELOS THERAPEUTICS, INC. (SEEL) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.